UB Paderborn / Katalog / Suche / in CDI

Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect

Biochemical pharmacology, 2012-03, Vol.83 (6), p.715-722

2012

Link zum Volltext

Verfügbarkeit prüfen

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy

Cancer prevention research (Philadelphia, Pa.), 2015-04, Vol.8 (4), p.296-302

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

Cancer prevention research (Philadelphia, Pa.), 2011-03, Vol.4 (3), p.347-353

2011

Link zum Volltext

Verfügbarkeit prüfen

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo

Biochemical pharmacology, 2012-03, Vol.83 (6), p.723-732

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations

Cancer epidemiology, biomarkers & prevention, 2008-03, Vol.17 (3), p.674-679

2008

Link zum Volltext

Verfügbarkeit prüfen

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients

Cancer genomics & proteomics, 2009, Vol.6 (1), p.41-50

2009

Link zum Volltext

Verfügbarkeit prüfen

NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S -nitrosylation

Cancer letters, 2010-12, Vol.298 (2), p.204-211

2010

Link zum Volltext

Verfügbarkeit prüfen

Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

Biochemical pharmacology, 2012-03, Vol.83 (6), p.733-740

2012

Link zum Volltext

Verfügbarkeit prüfen

Green Tea Extract-Induced Lethal Toxicity in Fasted but Not in Nonfasted Dogs

International journal of toxicology, 2011-02, Vol.30 (1), p.19-20

2011

Link zum Volltext

Verfügbarkeit prüfen

Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model

Cancer prevention research (Philadelphia, Pa.), 2014-02, Vol.7 (2), p.246-254

2014

Link zum Volltext

Verfügbarkeit prüfen

The CDER Labeling and Nomenclature Committee: Structure, Function, and Process

Therapeutic innovation & regulatory science, 1997, Vol.31 (1), p.7-11

Boring, Daniel L.

1997

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1353: Hydrogen sulfide-releasing naproxen inhibits HT-29 human colon cancer cell growth: Modulation of NF-κB

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1353-1353

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1349: Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1349-1349

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4608: Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4608-4608

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5560: All three positional isomers of acetyl salicylic acids are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5560-5560

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 807: Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.807-807

2011

Link zum Volltext

Verfügbarkeit prüfen

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers

Cancer prevention research (Philadelphia, Pa.), 2009-11, Vol.2 (11), p.951-956

2009

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects

Journal of clinical pharmacology, 2013-04, Vol.53 (4), p.403-412

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1849: Chemopreventive efficacy of naproxen, sulindac, and their nitric oxide-derivatives in the hydroxylbutyl(butyl)nitrosamine induced model of urinary bladder cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1849-1849

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 962: Similar preventive effects of naproxen and NO-naproxen in a chemically-induced model of urinary bladder cancer: Dose dependency, gene expression and toxicity

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.962-962

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1487: Nitric oxide-releasing NSAIDs suppress NF-κB signaling and increase caspase-3 enzyme activity in vitro and in vivo through S-nitrosylation

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1487-1487

2010

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents

Bioorganic & medicinal chemistry letters, 2011-12, Vol.21 (23), p.7146-7150

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo

Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients

NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S -nitrosylation

Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

Green Tea Extract-Induced Lethal Toxicity in Fasted but Not in Nonfasted Dogs

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model

The CDER Labeling and Nomenclature Committee: Structure, Function, and Process

Abstract 1353: Hydrogen sulfide-releasing naproxen inhibits HT-29 human colon cancer cell growth: Modulation of NF-κB

Abstract 1349: Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo

Abstract 4608: Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression

Abstract 5560: All three positional isomers of acetyl salicylic acids are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition

Abstract 807: Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers

Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects

Abstract 1849: Chemopreventive efficacy of naproxen, sulindac, and their nitric oxide-derivatives in the hydroxylbutyl(butyl)nitrosamine induced model of urinary bladder cancer

Abstract 962: Similar preventive effects of naproxen and NO-naproxen in a chemically-induced model of urinary bladder cancer: Dose dependency, gene expression and toxicity

Abstract 1487: Nitric oxide-releasing NSAIDs suppress NF-κB signaling and increase caspase-3 enzyme activity in vitro and in vivo through S-nitrosylation

Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents

Suchergebnisse filtern